Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319–332. https://doi.org/10.1056/nejmoa2211582
Authors:
Jennifer R. Brown
Barbara Eichhorst
Peter Hillmen
Wojciech Jurczak
Maciej Kaźmierczak
Nicole Lamanna
Susan O’Brien
Constantine S. Tam
Lugui Qiu
Keshu Zhou
Martin Šimkovič
Jiří Mayer
Amanda Gillespie-Twardy
Alessandra Ferrajoli
Peter Ganly
Robert Weinkove
Sebastian Grosicki
Andrzej Mital
Tadeusz Robak
Anders Österborg
Habte Yimer
Tommi Salmi
Megan-Der-Yu Wang
Lina Fu
Jessica Li
Kenneth Wu
Aileen Cohen
Mazyar Shadman
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Diagnosis and Treatment of Gastrointestinal Stromal Tumors (OpenAlex Topic)
Antineoplastic Agents (MeSH)
Heart Diseases (MeSH)
Leukemia, Lymphocytic, Chronic, B-Cell (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1056/nejmoa2211582
PMID:
36511784
DOI:
10.1056/nejmoa2211582
Journal:
New England Journal of Medicine
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View Web of Science Record

Record Created: